[Adjuvant Lung Cancer Therapy in the Elderly: Comparative Analysis of Indication, Adherence to Therapy, and Long Term...

Lung cancer is frequently diagnosed among elderly patients. However, this patient group is under-represented in or excluded from clinical trials and, therefore, evidence-based treatment is challenging. It is uncertain whether there are differences in the feasibility of adjuvant therapies between older and younger patients with NSCLC. The objective of this study was the analysis of treatment recommendations, adherence to adjuvant therapy, and overall survival in patients of at least 70 years of age with resected stage II, III or oligometastatic IV NSCLC in comparison to younger patients.

316 patients with NSCLC stage II to IV oligo resected with curative intent at the Giessen University Hospital between 2008 and 2019 were included, 115 of them 70 years or older. Patient and tumor characteristics, treatment type and survival data were extracted from the oncological database of the Mittelhessen lung cancer centre. Primary endpoints were indication and adherence to adjuvant treatment. Secondary endpoints were therapy-associated morbidity and overall survival.

Elderly received significantly fewer recommendations for adjuvant therapy, both chemotherapy (OR=0.509) and radiochemotherapy (OR=0.455). Compared to younger patients, elderly patients commenced therapy significantly less often (OR=4.49) and were less likely to complete treatment (OR=0.423). The 5-year survival rates of treated elderly patients treated exceeded those of untreated elderly (Stage II, 51.9 vs 31.8%; stage III, 29.0 vs 25.8%), and were inferior to the survival rates of the younger patients (stage II, 69.8 vs. 69.8%; stage III 52.8 vs. 19.7%).

In general, adjuvant therapy appears to be useful and feasible in selected patients over 70 years of age. However, its implementation and success are limited compared to younger patients. Adjuvant therapy is recommended and performed less frequently in older patients. The number of elderly patients treated remained unchanged over time, despite an increasing amount of therapy recommendations. Since the postoperative course, comorbidities, frailty and the toxicity of the therapy play a major role, the assessment of each individual case in an interdisciplinary oncological conference should serve as the basis for therapy decisions instead of age. Further studies are needed to collect representative data for the general elderly population. Newer, potentially better tolerated drugs such as tyrosine kinase inhibitors or immune checkpoint inhibitors appear to be promising.